<DOC>
	<DOC>NCT00148382</DOC>
	<brief_summary>The purpose of this study is to investigate the amount of metabolites of ATL-962 in the blood and to investigate the effect of ATL-962 on the amount of fat that is excreted in the faeces in subjects who are obese</brief_summary>
	<brief_title>Study of the Blood Levels and Effects of ATL-962 on Fat Excretion in Obese Subjects</brief_title>
	<detailed_description>Obesity is a significant and increasing clinical problem. There is a need for effective therapeutic agents to help people reduce weight. ATL-962 is a lipase inhibitor which could reduce the amount of fat absorbed from a person's diet, leading to weight reduction.</detailed_description>
	<criteria>Obese, otherwisehealthy subjects Body mass index 3045kg/m2 Women who are pregnant or breast feeding Any drug treatment within 2 weeks of commencement of dosing in this study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>Obesity</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>